Investing.com -- Redhill Biopharma Ltd (NASDAQ:RDHL) stock surged 6.2% on Tuesday after the specialty biopharmaceutical company announced a significant legal victory against Kukbo Co. Ltd.
The New York Supreme Court’s summary judgment in favor of RedHill is now final and eligible for enforcement and foreign recognition, with no further appeal possible following the expiration of the appeal period. The court has awarded RedHill more than $10.5 million in total, including approximately $8.6 million in the main judgment and around $1.9 million for legal fees and expenses.
The main judgment is immediately enforceable, while the legal fees award remains subject to appeal until March 13, 2026. Both awards continue to accrue 9% annual statutory interest. Additionally, RedHill has secured a Korean court attachment grant against Kukbo to prevent the company from disposing of assets prior to judgment enforcement.
RedHill Biopharma is primarily focused on developing and commercializing drugs for gastrointestinal diseases, infectious diseases, and oncology in the United States. The company promotes Talicia, an FDA-approved gastrointestinal drug for treating Helicobacter pylori infection in adults, which it co-commercializes with Cumberland Pharmaceuticals.
The company’s late-stage development pipeline includes several candidates: opaganib, an anti-inflammatory with potential applications for radiation exposure and COVID-19; RHB-204 for Crohn’s disease and pulmonary nontuberculous mycobacteria disease; RHB-107 for COVID-19 and other inflammatory conditions; and RHB-102 for chemotherapy-induced nausea and vomiting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.










